FDA, EU Need Common Adverse Reaction Definitions, Lilly’s Simmons Says
Executive Summary
FDA and European regulators should adopt a common definition for what adverse reactions must be reported, Lilly Global Product Safety Advisor Valerie Simmons, MD, said